We strongly support Louisiana Senate Bill 94, which would require health insurers to accept and count payments made on behalf of patients for prescription drugs towards their deductible and out-of-pocket maximum. This bill has already passed the Senate is scheduled to be voted on in the House this week. We urge you to support this critical bill for patients.
Testimony for the Record House Appropriations Subcommittee on Labor, HHS, Education, and Related Agencies (FY 2022)
On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of increased funding for domestic HIV and hepatitis programs in the FY 2022 Labor, HHS spending bill.
Vote “YES” on Louisiana SB 94 so that patients can afford prescription medications
We strongly support Senate Bill 94, which would require health insurers to accept and count payments made on behalf of patients for prescription drugs towards their deductible and out-of-pocket maximum. This bill is scheduled to be voted on in the Senate on Monday, May 10th. We urge you to support this critical bill for patients.
Support of Oregon SB 560 so that patients can afford their prescription medications
The HIV+Hepatitis Policy Institute strongly supports Oregon Senate Bill 560, which would require health insurers and health care service contractors to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums.
Support of the PBM Accountability Study Act (HR 1829)
The HIV+Hepatitis Policy Institute strongly supports The PBM Accountability Study Act (HR 1829), which would require the Government Accountability Office to provide a comprehensive report to Congress on the ways in which PBMs influence the pricing of pharmaceuticals, impede competition, use rebates and also provide recommendations on ways to lower prescription drug costs.